1  Introduction
Fast and extended knowledge is becoming available on the new viral disease that emerged in December 2019, causing enormous challenges at international levels. The pathology of this obscure virus, named Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2), is characterized by many patients remaining asymptomatic or with only benign symptoms, but this disease becomes life-threatening in some patients and requires hospitalization in intensive care units or resuscitation [1,2], and is often with a fatal outcome, yet to be fully established. Activation of the hemostasis system has been observed in many patients with severe complications, with occurrence of disseminated intravascular coagulopathy (DIC) or pulmonary embolism (PE), and multiorgan failure [3]. DDimer is frequently elevated, and the disease prognosis worsens with its increasing concentration [2]. Sepsis can also be present in some cases. Anticoagulant therapy, especially with LMWH, can improve the disease evolution and reduce the lethality incidence [4]. In addition, many patients with severe complications face a sudden worsening, starting 7 to > 14 days after the preliminary symptoms, although the immune response is effective with the presence of IgG and/or IgMs and is expected to fight the disease by controlling its pathological evolution [5,6]. This worsening is associated with an exacerbated immunological activity, a strong inflammatory response, and a cytokine storm [7]. New therapeutic approaches rely on controlling the pro-inflammatory cytokines, mainly IL-6, IL-10, and TNF-α. Lastly, there is a strong association of disease severity with age and presence of comorbidities, mainly hypertension, diabetes, obesity, chronic obstructive pulmonary disease and cardiovascular diseases (CVD). However, complications can also occur in younger persons without any known risk factors [1,2].